Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view

Blood

Volumn 98, Issue 13, 2001, Pages 3541-3553

  Schimmer, Aaron D ^a,b   Hedley, David W ^a   Penn, Linda Z ^a   Minden, Mark D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE 8; CYTOCHROME C; CYTOKINE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LEUKEMIA; APOPTOSIS; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; HUMAN; MITOCHONDRION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; RNA TRANSLATION; SECOND MESSENGER;

EID: 0035895056     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3541     Document Type: Review

References (173)

1. Wang PP, Haines CS. Childhood and adolescent leukaemia in a North American population. Int J Epidemiol. 1995;6:1100-1109.
2. Bricker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep. 1985;69:5-11.
3. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multi drug resistance (mdr1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood. 1997;89:3323-3329.
4. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
5. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513-519.
6. 2- ions. J Biol Chem. 1998;143:217-224.
7. Sheikh MS, Fornance AJ. Death and decoy receptors and p53-mediated apoptosis. Leukemia. 2000;14:1509-1513.
8. Baker S, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1998;17:3261-3270.
9. Warzocha K, Salles G. The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. Leuk Lymphoma. 1998;29:81-92.
10. Tsumimoto Y, Shimizu S. Bcl-2 family: life or death switch. FEBS. 2000;466:6-10.
11. Kelekar A, Thompson CB. Bcl-2 family of proteins: the role of the BH3 domain in apoptosis. Trends Cel Biol. 1998;8:324-330.
12. Fadeel B, Orrenius S, Zhivotovsky B. The most unkindest cut of all: the multiple roles of mammalian caspases. Leukemia. 2000;14:1514-1525.
13. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17:3237-3245.
14. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410:549-554.
15. Rokhlin OW, Glover RA, Cohen MB. Fas mediated apoptosis in human prostate carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res. 1998;58:5870-5875.
16. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from the mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
17. Saleh A, Srinivasula SM, Acharay S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem. 1999;274:17941-17945.
18. Zou H, Li Y, Liu X, Wang X. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549-11556.
19. Hu Y, Ding L, Spencer DM, Nunez G. WD-40 repeat region regulates Apaf-1 self-associated and procaspase-9 activation. J Biol Chem. 1998;273:33489-33494.
20. Kang JJ, Schaber MD, Srinivasula SM, et al. Cascades of mammalian caspases activation in the yeast Saccharomyces cervesisiae. J Biol Chem. 1999;274:3189-3198.
21. Stennicke HR, Jurgensmeier JM, Shin W, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem. 1998;273:27084-27090.
22. Zapata JM, Takahashi R, Salvesen GS, Reed JC. Granzyme release and caspase activation in activated human T-lymphocytes. J Biol Chem. 1998;273:6916-6920.
23. Barry M, Heibein JA, Pinkoski MJ, et al. Granzyme b short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol. 2000;20:3781-3794.
24. Atkinson EA, Barry M, Darmon AJ, et al. Cytotoxic T lymphocyte-assisted suicide. J Biol Chem. 1998;273:21261-21266.
25. Chang HY, Yang X, Baltimore D. Dissecting fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc Natl Acad Sci U S A. 1999;96:1252-1256.
26. Berglund H, Olerenshaw D, Sankar A, Federwisch M, McDonald NQ, Driscoll PC. The threedimensional solution structure and dynamic properties of the human FADD death domain. J Mol Biol. 2000;302:171-188.
27. Buschmann T, Potopova O, Bar-Shira A, et al. Jun NH2-terminal kinase phosphorylation of p53 and Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. J Biol Chem. 2001;21:2743-2754.
28. Ip Y, Davis R. Signal transduction by the c-Jun N terminal kinase (JNK)- from inflammation to development. Curr Opin Cell Biol. 1998;10:205-219.
29. Kharbanda S, Saxena S, Yoshida K, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem. 2000;275:322-327.
30. Tsao DH, McDonagh T, Telliez JB, et al. Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key stop in the TNFR1 signaling pathway. Mol Cell. 2000;5:1051-1057.
31. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81:495-504.
32. Han Y, Brasier AR. Mechanism for biphasic Rel A-NF kB1 nuclear translocation in tumor necrosis factor α-stimulated hepatocytes. J Biol Chem. 1997;272:9825-9832.
33. κB-control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
34. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NFKB antiapoptosis: induction of TRAF2 and c-IAP1 and cIAP2 to suppress caspase-8 activation. Science. 1998;218:1680-1683.
35. Willis T, Jadayel D, Du M, Peng H, Perry A, Abdul-Rauf MEA. Bcl10 is involved in t(1;14)(p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35-45.
36. Liu T, Lin P, Chang J, et al. Mutation analysis of Bcl-10 in acute myeloid leukaemia. Br J Hematol. 2000;109:248-253.
37. Cai J, Yang J, Jones D. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta. 1998;1366:139-149.
38. Eastman A, Rigas J. Modulation of apoptosis signaling pathways and cell cycle regulation. Semin Oncol. 1999;5(suppl 16):7-16.
39. Rowan S, Fisher DE. Mechanisms of apoptotic cell death. Leukemia. 1997;11:457-465.
40. Wesselborg S, Engels I, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999;93:3053-3063.
41. Mansat V, Bettaieb A, Levade T, Laurent G, Jaffrezou J. Serine protease inhibitors block neural sphingomyelinase activation, ceramide generation and apoptosis triggered by daunorubicin. FASEB J. 1997;11:695-702.
42. Kim C, Wang X, Huang Y, et al. Overexpression of Bcl-X(L) inhibits ARa-C induced mitochondrial loss of cytochrome c and other pertubations that activate the molecular cascade of apoptosis. Cancer Res. 1997;57:3115-3120.
43. Tournier C, Hess P, Yang D, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-874.
44. Mathias S, Pena L, Kolesknick RN. Signal transduction of stress via ceramide. Biochem J. 1998;335:465-480.
45. Kristal B, Brown A. Apoptogenic gangloiside GD3 directly induces the mitochondrial permeability transition. J Biol Chem. 1999;274:23169-23175.
46. Verheij M, Bose R, Lin X, et al. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis. Nature. 1996;380:75-79.
47. Norbury C, Hickson I. Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol. 2001;41:367-401.
48. Daniel P. Dissecting the pathways to death. Leukemia. 2000;14:2035-2044.
49. Zhan Q, Fan S, Bai I, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 1994;9:3743-3751.
50. Asher G, Lotem J, Cohen B, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2000;98:1188-1193.
51. Hermeking H, Eick D. Mediation of c-Myc induced apoptosis by p53. Science. 1994;265:2091-2093.
52. Chang D, Claassen G, Hann S, Cole M. The cmyc transactivation domain is a direct modulator of apoptosic versus proliferative signals. Mol Cell Biol. 2000;20:4309-4319.
53. Zindy F, Eischen C, Randle D, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424-2433.
54. Vousden K. p53: death star. Cell. 2000;103:691-694.
55. Weber J, Taylor L, Roussel M, Sherr C, Bar-Sagi D. Nuclear Arf sequesters Mdm2 and activates p53. Nature. 1999;1:20-26.
56. Soucie E, Annis M, Sedivy J, et al. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol Cell Biol. 2001;21:4725-4736.
57. King K, Cidlowski J. Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998;60:601-617.
58. Pham N, Hedley D. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Research. 2001;264:345-352.
59. Hossain K, Akhand A, Kato M, et al. Arsenite induces apoptosis of murine T lymphocytes through membrane Raft-linked signaling for activation of c-Jun amino-terminal kinase. J Immunol. 2000;165:4290-4297.
60. Jiang X, Chun-Yu Wong B, Yuen S, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and caspase-3. Int J Cancer. 2001;91:173-179.
61. Narita M, Shimizu S, Ito T, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:14681-14686.
62. Brenner C, Cadiou H, LaViera H, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene. 2000;19:329-336.
63. Rostovtseva T, Colombini M. ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane. J Biol Chem. 1996;271:28006-28008.
64. Liu MY, Colombini M. Regulation of mitochondrial respiration by controlling the permeability of the outer membrane through the mitochondrial channel, VDAC. Biochim Biophys Acta. 1992;1098:255-260.
65. Pastorino JG, Tafani M, Rothman RJ, Marcineviciute A, Hoek JB, Farber JL. Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore. J Biol Chem. 1999;274:31734-31739.
66. Basanez G, Nechushtan A, Drozhinin O, et al. Bax, but not Bcl-xL decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci U S A. 1999;96:5492-5497.
67. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science. 1997;277:370-372.
68. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL an inhibitor of programmed cell death. Nature. 1996;381:335-341.
69. Petros A, Medek A, Nettesheim D, et al. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A. 2001;98:3012-3017.
70. Liang H, Fesik SW. Three-dimensional structures of proteins involved in programmed cell death. J Mol Biol. 1997;274:291-302.
71. Ottilie S, Diaz JL, Horne W, et al. Dimerization properties of human BAD. J Biol Chem. 1997;272:30866-30872.
72. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer K. BH3 domain of BAD is required for heterodimerization with Bcl-xL and pro-apoptotic activity. J Biol Chem. 1997;272:24101-24104.
73. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027-2031.
74. Ottvai ZN, Milliman CL, Korsmeyer K. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
75. Schimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci U S A. 2000;97:3100-3105.
76. Cheng EHY, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 1997;278:1966-1968.
77. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby LM, Bredesen DE, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl Acad Sci U S A. 1998;95:4997-5002.
78. Kane DJ, Safafian TA, Anton R, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 1993;262:1274-1277.
79. Hockenberry DM, Oltvai ZN, Yin X, Milliman CL, Korsmeyer K. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241-251.
80. Shimizu S, Shinohara Y, Tsujimoto Y. Bax and Bclxl independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene. 2000;19:4309-4318.
81. Schendel S, Xie Z, Montal M, Matsuyama S, Montal M, Reed JC. Channel formation by anti-apoptotic protein Bcl-2. Proc Natl Acad Sci U S A. 1997;94:5113-5118.
82. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem. 1996;271:12695-12698.
83. Furukawa Y, Iwase S, Kikuchi J, et al. Phosphorylation of Bcl-2 protein by cdc2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem. 2000;275:21661-21667.
84. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997;16:4628-4638.
85. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res. 1993;53:4701-4714.
86. Lee ST, Hoeflich KP, Wasfy GW, et al. Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene. 1999;18:3520-3528.
87. 2+ concentration within the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2000;97:5723-5728.
88. Kozopas K, Yang T, Buchan H, Zhou P, Craig R. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci U S A. 2001;83:3516-3520.
89. Zhou P, Qian L, Kozopas K, Craig R. Mcl-1, a Bcl-2 family member, delays the death of hematopoetic cells under a variety of apoptosi-inducing conditions. Blood. 1997;89:630-643.
90. Kaufmann S, Karp J, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
91. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer K. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285-291.
92. Zha J, Harada H, Yang E, Jackel J, Korsmeyer K. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell. 1996;87:619-628.
93. Zamzami N, El Hamel C, Maisse C, et al. Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene. 2000;19:6342-6350.
94. Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan B, Reed JC. Ion channel activity of the BH3 only Bcl-2 family member Bid. J Biol Chem. 1999;274:21932-21936.
95. Tang D, Lahti JM, Kidd V. Caspase-8 activation and bid cleavage contributes to MCF7 cellular execution in a casapse-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem. 2000;275:9303-9307.
96. Zhang H, Xu Q, Krajewski S, et al. BAR: an apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc Natl Acad Sci U S A. 2000;97:2597-2602.
97. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995;92:4507-4511.
98. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phoshorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253-1255.
99. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem. 1997;272:11671-11673.
100. Srivastava R, Mi Q, Hardwick J, Longo D. Deletion of the loop region of Bcl-2 completly blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A. 1999;96:3775-3780.
101. , Hu ZB, Minden MD, McCulloch EA. Phospharylation of Bcl-2 after exposure of human leukemic cells to retinoic acid. Blood. 1998;92:1768-1775.
102. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci U S A. 1998;95:7439-7444.
103. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
104. Harada H, Becknell B, Wilm M, et al. Phosphorylation and inactivation of BAD by mitochondriaanchored protein kinase A. Mol Cell. 1999;3:413-422.
105. Tan Y, Ruan H, Demeter MW, Comb MJ. p90rsk blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem. 1999;274:34859-34867.
106. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, ser155. Biochem J. 2000;349:547-557.
107. Zhou X, Liu Y, Payne G, Lutz RJ, Chittenden T. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on ser155. J Biol Chem. 2000;275:2506-25051.
108. Tan Y, Demeter MW, Ruan H, Comb MJ. BAD ser-155 phosphorylation regulates BAD/Bcl-xL interaction and cell survival. J Biol Chem. 2000;275:25865-25869.
109. 2+induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343.
110. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. Bad enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem. 1998;273:30419-30426.
111. Hayashi Y. The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol. 2000;37:368-380.
112. Cortez D, Kadlec K, Pendergast A. Structural and signaling requirements for BCR-ABL mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
113. Neshat M, Raitano A, Wang H, Reed JC, Sawyers C. The survival function of Bcr-Abl oncogene is mediated by Bad-dependent and independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20:1179-1186.
114. Hamdane M, David-Cordonnier M, D'Halluin J. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid line (P210BCR-ABL activates p65 NF-kappaB). Oncogene. 1997;15:2267-2275.
115. Reuther J, Reuther G, Cortez D, Pendergast A, Baldwin AJ. A requirement for NF-kappaB activation in Bcr-Abl mediated transformation. Genes Dev. 1998;12:968-981.
116. de Groot R, Raaiimakers J, Lammers J, Jove R, Koenderman L. STAT 5 activation by BCR-Abl contributes to transformation of K562 leukemic cells. Blood. 1999;94:1108-1112.
117. Gesbert F, Griffin J. Bcr/Abl activates transcription of Bcl-X gene through STAT 5. Blood. 2000;96:2269-2276.
118. Fang G, Kim C, Perkins C, et al. CG57148B (STI571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemic cells to apoptosis due to antileukemic drugs. Blood. 2000;96:2246-2253.
119. Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;334:1031-1037.
120. Druker B, Sawyers C, Kantarjian HM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
121. Grimwald D, Walker HOF, Wheatley K, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
122. Shinobu N, Maeda T, Aso T, et al. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem. 1999;274:17003-17010.
123. Melnick A, Licht J. Deconstructing a disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
124. Radich J. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:21-36.
125. Volm M, Zintl F, Sauerbrey A, Koomagi R. Proliferation and apoptosis in newly diagnosed and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19:4327-4332.
126. Prokop A, Wieder T, Sturm IEE, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2001;14:1606-1613.
127. Wada M, Bartram C, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993;82:3163-3169.
128. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (apo-1/fas) system in drug-resistant cells. Leukemia. 1997;11:1833-1841.
129. Eiechen CM, Kottke TJ, Basi GS, et al. Comparison of apoptosis in wild-type and fas-resistant cells: chemotherapy-induced apoptosis is not dependent on fas/fas ligand interactions. Blood. 1997;90:935-943.
130. Kamihira S, Yamada Y, Tomonaga M, Sugahara K, Tsuruda K. Discrepant expression of membrane and soluble isoforms of Fas (CD95/Apo-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis. Br J Hematol. 1999;107:851-860.
131. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-Flice, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem. 1997;272:17255-17257.
132. Campos L, Rouault J, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
133. Charpin C, Garcia S, Bonnier P, et al. Bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlations with 10-year follow-up. J Clin Oncol. 1998;16:2025-2031.
134. Couston-Smith E, Kitanaka A, Pui C, et al. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996;87:1140-1146.
135. Kornblau SM, Vu HT, Ruvolo P, et al. BAX and PKCα modulate the prognostic impact of Bcl-2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000;6:1401-1409.
136. Ong Y, McMullin M, Bailie K, Lappin TRJ, Jones F, Irvine A. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Hematol. 2000;111:182-189.
137. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6:1796-1803.
138. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Hematol. 2000;111:196-203.
139. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92:3090-3097.
140. Fardel S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999;5:4041-4047.
141. Svingen PA, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood. 2000;96:3922-3931.
142. Jo M, Kim T, Seol D, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature. 2000;6:564-567.
143. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis and nitrite release. J Immunol. 1995;154:1307-1316.
144. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol. 1991;138:447-453.
145. Wiley SR, Schooley K, Smolak P, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
146. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
147. Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells in mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001;7:680-686.
148. Ito Y, Pandey P, Place A, et al. The novel triterpenoid 2-cyano3, 12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Diff. 2000;11:261-267.
149. Nakayama K, Negishi I, Kuika K, Sawa H, Loh D. Targeted disruption of Bcl-2αβ in mice: occurrence of gray hair, polycystic disease, and lymphocytopenia. Proc Natl Acad Sci U S A. 1994;91:3700-3704.
150. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature haematopoietic cells and neurons in bcl-x-deficient mice. Science. 1995;267:1506-1510.
151. Park J, Bernstein I, Hockenberry DM. Primitive human haematopoietic precursors express Bcl-x but not Bcl-2. Blood. 2001;86:868-876.
152. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem. 1999;274:13298-13304.
153. Wang J, Zhang Z, Choksi S, et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000;60:1498-1502.
154. Fenton M, Bone N, Sinclain AJ. The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line. J Immunol Methods. 1998;212:41-48.
155. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444-10450.
156. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction delivery of a biologically active protein into the mouse. Science. 1999;285:156-159.
157. Wang J, Liu D, Zhang Z, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000;97:7124-7129.
158. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000;95:3929-3938.
159. Waters JS, Webb A, Cunningham D, et al. Phase 1 clinical and pharmacokinetic study of blc-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:1812-1823.
160. Joensuu H, Roberts P, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
161. Jarvis D, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Proc Natl Acad Sci U S A. 1994;54:1707-1714.
162. O'Gorman DM, McKenn SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia. 2000;14:602-611.
163. Koh H, Lee KH, Kim D, Kim S, Kim J, Chung J. Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced PRK2 cleavage. J Biol Chem. 2000;275:34451-34458.
164. Blondelle S, Houghten RA. Design of model amphipathic peptides having potent antimicrobial activities. Biochemistry. 1992;31:12688-12694.
165. Bessalle R, Kapitovsky A, Gorea A, Shalit I, Fridkin M. AII-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS. 1990;274:151-155.
166. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-1038.
167. Trippett T, Schlemmer S, Elisseyeff Y, et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood. 1992;5:1158-1162.
168. Campos L, Guyotat D, Archimabud E, et al. Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphocytic leukemia cells at diagnosis. Blood. 1992;79:473-476.
169. Zimm S, Reaman G, Murphy R, Poplack D. Biochemical parameters of mercaptopurine activity in patients with acute lymphocytic leukemia. Cancer Res. 1986;46:1495-1498.
170. Singer M, Mesner L, Friedman C, Trask BJ, Hamlin J. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci U S A. 2000;97:7921-7926.
171. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry. 1996;35:10004-10013.
172. Göker E, Waltham M, Kheradpour A, et al. Amplification of the dihyrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutation. Blood. 1995;86:677-684.
173. Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature. 1988;336:259-261.